Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A, Cancer. J Clin. 2025;75(1):10–45.

Google Scholar 

Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European association of urology guidelines on renal cell carcinoma: the 2025 update. Eur Urol. 2025;87(6):683–96.

Article  PubMed  Google Scholar 

Lucarelli G, Lasorsa F, Rutigliano M, Milella M, Spilotros M, d’Amati A, et al. The percentage abundance of sarcomatoid component has a prognostic role in grade 4 non-metastatic clear cell-renal carcinoma. World J Urol. 2025;43(1):243.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli G, Lasorsa F. Novel insights into molecular landscape of advanced renal cell carcinoma. Oncologie. 2025;27(2):319–23.

Article  Google Scholar 

Lucarelli G, Lasorsa F, Milella M, d’Amati A, Ingravallo G, Silecchia M, et al. Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma. Urologic Oncology: Seminars Original Investigations. 2025;43(8):e46919–32.

Article  Google Scholar 

Adeniran AJ, Shuch B, Humphrey PA. Sarcomatoid and rhabdoid renal cell carcinoma: Clinical, Pathologic, and molecular genetic features. Am J Surg Pathol. 2024;48(7):e65–88.

Article  PubMed  Google Scholar 

Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17(12):659–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trudeau V, Larcher A, Sun M, Boehm K, Dell’Oglio P, Sosa J, et al. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. World J Urol. 2016;34(10):1429–36.

Article  CAS  PubMed  Google Scholar 

Zhang BY, Thompson RH, Lohse CM, Leibovich BC, Boorjian SA, Cheville JC, et al. A novel prognostic model for patients with sarcomatoid renal cell carcinoma. BJU Int. 2015;115(3):405–11.

Article  PubMed  Google Scholar 

Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol. 2016;70(2):348–57.

Article  CAS  PubMed  Google Scholar 

Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tickoo SK, Alden D, Olgac S, Fine SW, Russo P, Kondagunta GV, et al. Immunohistochemical expression of hypoxia inducible Factor-1α and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177(4):1258–63.

Article  CAS  PubMed  Google Scholar 

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84.

Article  CAS  PubMed  Google Scholar 

Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conant JL, Peng Z, Evans MF, Naud S, Cooper K. Sarcomatoid renal cell carcinoma is an example of epithelial–mesenchymal transition. J Clin Pathol. 2011;64(12):1088–92.

Article  PubMed  Google Scholar 

Braga EA, Fridman MV, Loginov VI, Dmitriev AA, Morozov SG. Molecular mechanisms in clear cell renal cell carcinoma: role of MiRNAs and hypermethylated MiRNA genes in crucial oncogenic pathways and processes. Front Genet. 2019;10:320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salgia NJ, Aubrecht WM, Wang L, Ram B, Wasik BJ, Khan A, et al. Stratification of patients with renal cell carcinoma by the abundance of sarcomatoid features reveals differences in survival and the underlying pathobiology. Eur Urol Oncol. 2024;7(5):973–7.

Article  PubMed  PubMed Central  Google Scholar 

Greene CJ, Attwood K, Sharma NJ, Balderman B, Deng R, Muhitch JB, et al. Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis. Front Oncol. 2022;12:923043.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salgia NJ, Fujiwara Y, Xu B, George S, Muhitch JB, Kauffman EC. Biological and clinical insight into the prevention and management of metastatic renal cell carcinoma with a sarcomatoid component. Eur Urol Focus. 2025;11(3):421–4.

Article  PubMed  Google Scholar 

di Meo NA, Lasorsa F, Rutigliano M, Loizzo D, Ferro M, Stella A, et al. Renal cell carcinoma as a metabolic disease: an update on main Pathways, potential Biomarkers, and therapeutic targets. Int J Mol Sci. 2022;23(22):14360.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407.

Article  CAS  PubMed  Google Scholar 

Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, et al. Metabolomic profile of Glycolysis and the Pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371–86.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli G, Rutigliano M, Sallustio F, Ribatti D, Giglio A, Lepore Signorile M, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

di Meo NA, Lasorsa F, Rutigliano M, Milella M, Ferro M, Battaglia M, et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297–313.

Article  PubMed  Google Scholar 

Lucarelli G, Rutigliano M, Loizzo D, di Meo NA, Lasorsa F, Mastropasqua M, et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. Int J Mol Sci. 2022;23(22):13968.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, et al. Grade-Dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 2015;75(12):2541–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–15.

Article  PubMed  PubMed Central  Google Scholar 

Młynarczyk G, Mikłosz A, Suchański J, Reza S, Romanowicz L, Sobolewski K, et al. Grade-dependent changes in sphingolipid metabolism in clear cell renal cell carcinoma. J Cell Biochem. 2022;123(4):819–29.

Article  PubMed  Google Scholar 

Lucarelli G, Rutigliano M, Ferro M, Giglio A, Intini A, Triggiano F, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urol Oncol. 2017;35(7):e46115–27.

Article  Google Scholar 

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, et al. Sarcomatoid renal cell carcinoma has a distinct molecular Pathogenesis, driver mutation Profile, and transcriptional landscape. Clin Cancer Res. 2017;23(21):6686–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis Blockade. Cancer Cell. 2020;38(6):803–e8174.